Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for Intractable Pain in Advanced Cancer
NCT05067257Phase 2Suspended
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resiniferatoxin in cancer pain, sponsored by Sorrento Therapeutics. Started Sep 2025; status: suspended.
02
Drugs
resiniferatoxin
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT05067257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067257.